Explore

Rapid Read Rapid Read
23andMe Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects

23andMe Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects

The 23andMe Research Institute has published a study in Nature identifying genetic predictors for the efficacy and side effects of GLP-1 receptor agonists, which are medications used in weight management. The study involved a genome-wide association study (GWAS) of 27,885 individuals using GLP-1 medications like semaglutide and tirzepatide. The research found that genetic variations in the GLP1R and GIPR genes influence the effectiveness of these medications and the likelihood of side effects such as nausea and vomiting. The study highlights the potential for personalized treatment strategies in obesity management, based on genetic testing.
Rapid Read Rapid Read
23andMe Study Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects

23andMe Study Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects

The 23andMe Research Institute has published a study in Nature identifying genetic predictors that influence the efficacy and side effects of GLP-1 receptor agonists, such as semaglutide and tirzepatide, used in weight management. The study involved a genome-wide association study (GWAS) of 27,885 individuals, revealing that variations in the GLP1R and GIPR genes are linked to differences in weight loss efficacy and side effects like nausea and vomiting. These findings suggest that genetic testing could guide more personalized treatment strategies for obesity, addressing the variability in patient responses to these medications.
Rapid Read Rapid Read
Study Identifies Genetic Predictors for GLP1 Receptor Agonist Weight Loss

Study Identifies Genetic Predictors for GLP1 Receptor Agonist Weight Loss

A study published in Nature has identified genetic predictors that influence the efficacy and side effects of GLP1 receptor agonists, medications used for weight loss. Conducted by researchers using data from 23andMe participants, the study analyzed the genetic factors that affect how individuals respond to these medications. The research focused on two main drugs, semaglutide and tirzepatide, and examined the relationship between genetic variations and the drugs' effectiveness in reducing body mass index (BMI) and potential side effects. The study utilized both self-reported data and electronic health records to ensure accuracy and comprehensiveness.
Rapid Read Rapid Read
Genetic Variants Linked to Varied Responses to Obesity Drugs Identified by 23andMe

Genetic Variants Linked to Varied Responses to Obesity Drugs Identified by 23andMe

A study published in Nature by 23andMe has identified genetic variants that explain the varied responses to obesity drugs like semaglutide and tirzepatide. The research involved nearly 28,000 participants who used 23andMe's DNA-testing service and reported their experiences with weight-loss drugs. The study found that specific genetic variants are associated with greater weight loss and increased risk of side effects such as nausea. These findings provide insights into why some individuals experience significant weight loss while others do not, highlighting the role of genetics in drug efficacy and side effects.
Rapid Read Rapid Read
Genetic Study Reveals Variability in GLP-1 Drug Efficacy and Side Effects

Genetic Study Reveals Variability in GLP-1 Drug Efficacy and Side Effects

A recent study published in Nature has identified genetic variants that influence the efficacy and side effects of GLP-1 receptor agonists, a class of drugs used for weight loss. The research involved a genome-wide association study (GWAS) with 27,885 participants, revealing that a missense variant in the GLP1R gene is associated with enhanced weight-loss efficacy. Each copy of the effect allele predicted an additional 0.76 kg of weight loss. Additionally, genetic variations in GLP1R and GIPR were linked to medication-induced nausea and vomiting, particularly in patients using tirzepatide. The study highlights the role of genetic differences in drug-target genes in modulating therapeutic responses and adverse events.
Rapid Read Rapid Read
23andMe Study Identifies Genetic Variants Affecting Obesity Drug Efficacy and Side Effects

23andMe Study Identifies Genetic Variants Affecting Obesity Drug Efficacy and Side Effects

A study conducted by the research arm of genetic testing company 23andMe has identified genetic variations that influence the effectiveness and side effects of GLP-1 agonist-based weight-loss drugs. The study analyzed the genomes of nearly 28,000 users of these drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Researchers found a missense variant in the GLP1R gene associated with greater weight loss and multiple variants in the GIPR gene linked to increased susceptibility to side effects like nausea and vomiting. These findings, published in the journal Nature, suggest that genetic testing could help tailor weight-loss treatments to individual patients, enhancing efficacy and safety.
Trendline Trendline
23andMe Study Reveals Genetic Variations Affecting Obesity Drug Efficacy

23andMe Study Reveals Genetic Variations Affecting Obesity Drug Efficacy

23andMe Study Reveals Genetic Variations Affecting Obesity Drug Efficacy
Trendline Trendline
23andMe Study Reveals Genetic Factors in Obesity Drug Efficacy

23andMe Study Reveals Genetic Factors in Obesity Drug Efficacy

23andMe Study Reveals Genetic Factors in Obesity Drug Efficacy
Rapid Read Rapid Read
Vanderbilt Health Study Reveals Tradeoffs in Weight Loss Treatments Affecting Body Composition

Vanderbilt Health Study Reveals Tradeoffs in Weight Loss Treatments Affecting Body Composition

A study conducted by Vanderbilt Health has highlighted the tradeoffs involved in popular weight loss treatments, including bariatric surgery and GLP-1 receptor agonist drugs. The research, published in JAMA Network Open, indicates that while these treatments lead to significant fat loss, they also result in a reduction of fat-free mass, which includes lean muscle. The study analyzed data from 1,257 patients who underwent bariatric surgery and 1,809 patients treated with semaglutide or tirzepatide. The researchers used bioelectrical impedance analysis to assess changes in body composition over a 24-month period. The findings show that both treatments produce similar patterns of substantial fat mass reduction and modest decreases in fat-free mass, with an overall improvement in body composition.
Trendline Trendline
New Study Reveals Metabolic Benefits of Tirzepatide Beyond Weight Loss

New Study Reveals Metabolic Benefits of Tirzepatide Beyond Weight Loss

New Study Reveals Metabolic Benefits of Tirzepatide Beyond Weight Loss
Rapid Read Rapid Read
NIH Researchers Develop New Opioid with Reduced Addiction Risk

NIH Researchers Develop New Opioid with Reduced Addiction Risk

Researchers at the National Institutes of Health (NIH) have developed a new opioid compound that offers strong pain relief without the typical risks of addiction and respiratory depression. This new compound, derived from a class of synthetic opioids known as nitazenes, was tested in laboratory animals and showed promising results. The study, published in Nature, highlights the compound's ability to provide effective pain relief while minimizing adverse effects commonly associated with opioids. The research team focused on modifying the nitazenes to retain their pain-relieving properties while reducing their potency to improve safety. The compound, referred to as DFNZ, demonstrated a safer pharmacological profile, avoiding respiratory depression and showing minimal withdrawal symptoms in preclinical tests.
Rapid Read Rapid Read
Adenosine Surges Identified as Key in Ketamine's Antidepressant Effects

Adenosine Surges Identified as Key in Ketamine's Antidepressant Effects

A study published in Nature has identified adenosine surges as a key mechanism in the rapid antidepressant effects of ketamine. Researchers found that ketamine triggers fast, dose-dependent increases in extracellular adenosine within mood-regulatory circuits, particularly in the medial prefrontal cortex. This discovery challenges previous assumptions that ketamine's effects were solely due to NMDA receptor antagonism. The study suggests that adenosine signaling plays a central role in ketamine's ability to rapidly alleviate depression symptoms, offering new insights into its therapeutic potential.